Page 176«..1020..175176177178..190200..»

Relief Therapeutics and Acer Therapeutics Sign Option Agreement for Exclusivity to Negotiate a Collaboration and License Agreement for the Worldwide…

By Dr. Matthew Watson

Acer to receive $1 million payment to obtain exclusivity and a $4 million loan from Relief

Read this article:
Relief Therapeutics and Acer Therapeutics Sign Option Agreement for Exclusivity to Negotiate a Collaboration and License Agreement for the Worldwide...

To Read More: Relief Therapeutics and Acer Therapeutics Sign Option Agreement for Exclusivity to Negotiate a Collaboration and License Agreement for the Worldwide…
categoriaGlobal News Feed commentoComments Off on Relief Therapeutics and Acer Therapeutics Sign Option Agreement for Exclusivity to Negotiate a Collaboration and License Agreement for the Worldwide… | dataJanuary 25th, 2021
Read All

Todos Medical Announces Strategic Investment by Yozma Group Korea

By Dr. Matthew Watson

NEW YORK, NY, REHOVAT, ISRAEL, SOUTH KOREA, Jan. 25, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire --Todos Medical (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis and developing blood tests for early detection of cancer and Alzheimer’s disease, today announced a $3.4 million strategic investment (the “Investment”) from tech-focused venture capital firm Yozma Group Korea (“Yozma”).

Original post:
Todos Medical Announces Strategic Investment by Yozma Group Korea

To Read More: Todos Medical Announces Strategic Investment by Yozma Group Korea
categoriaGlobal News Feed commentoComments Off on Todos Medical Announces Strategic Investment by Yozma Group Korea | dataJanuary 25th, 2021
Read All

Neuropathix, Inc. CEO Recaps 2020 Advances and Potential Ahead

By Dr. Matthew Watson

DOYLESTOWN, Pa., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB: NPTX), a socially responsible pain management life sciences company, announced today that it has issued a letter to its shareholders providing commentary on the Company’s recent initiatives and corporate updates.

Visit link:
Neuropathix, Inc. CEO Recaps 2020 Advances and Potential Ahead

To Read More: Neuropathix, Inc. CEO Recaps 2020 Advances and Potential Ahead
categoriaGlobal News Feed commentoComments Off on Neuropathix, Inc. CEO Recaps 2020 Advances and Potential Ahead | dataJanuary 25th, 2021
Read All

Information regarding the results of mandatory redemption of shares

By Dr. Matthew Watson

Information regarding the results of mandatory redemption of shares

Original post:
Information regarding the results of mandatory redemption of shares

To Read More: Information regarding the results of mandatory redemption of shares
categoriaGlobal News Feed commentoComments Off on Information regarding the results of mandatory redemption of shares | dataJanuary 25th, 2021
Read All

Tauriga Sciences Inc. Completes the Package Design for Its Cherry Lime Rickey Flavor, Caffeine Infused Tauri-Gum Version

By Dr. Matthew Watson

Excerpt from:
Tauriga Sciences Inc. Completes the Package Design for Its Cherry Lime Rickey Flavor, Caffeine Infused Tauri-Gum Version

To Read More: Tauriga Sciences Inc. Completes the Package Design for Its Cherry Lime Rickey Flavor, Caffeine Infused Tauri-Gum Version
categoriaGlobal News Feed commentoComments Off on Tauriga Sciences Inc. Completes the Package Design for Its Cherry Lime Rickey Flavor, Caffeine Infused Tauri-Gum Version | dataJanuary 25th, 2021
Read All

Valneva and Instituto Butantan Sign Final Agreement on Single-Shot Chikungunya Vaccine for Low and Middle Income Countries

By Dr. Matthew Watson

Saint-Herblain (France), Sao Paulo, (Brazil), January 25, 2021 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company focused on prevention of infectious diseases with significant unmet medical need, and Instituto Butantan, producer of immunobiologic products, today announced the signing of definitive agreements for the development, manufacturing and marketing of Valneva’s single-shot chikungunya vaccine, VLA1553, in Low and Middle Income Countries (LMICs). This finalization follows the signing of a binding term sheet in May 20201.  The collaboration falls within the framework of the $23.4 million funding agreement Valneva signed with the Coalition for Epidemic Preparedness Innovations (CEPI) in July 20192.

Read more here:
Valneva and Instituto Butantan Sign Final Agreement on Single-Shot Chikungunya Vaccine for Low and Middle Income Countries

To Read More: Valneva and Instituto Butantan Sign Final Agreement on Single-Shot Chikungunya Vaccine for Low and Middle Income Countries
categoriaGlobal News Feed commentoComments Off on Valneva and Instituto Butantan Sign Final Agreement on Single-Shot Chikungunya Vaccine for Low and Middle Income Countries | dataJanuary 25th, 2021
Read All

Eurobio Scientific: EXCEPTIONAL 2020 TURNOVER OF € 189 MILLION (+ 220%)

By Dr. Matthew Watson

EXCEPTIONAL 2020 TURNOVER OF € 189 MILLION (+ 220%)

More:
Eurobio Scientific: EXCEPTIONAL 2020 TURNOVER OF € 189 MILLION (+ 220%)

To Read More: Eurobio Scientific: EXCEPTIONAL 2020 TURNOVER OF € 189 MILLION (+ 220%)
categoriaGlobal News Feed commentoComments Off on Eurobio Scientific: EXCEPTIONAL 2020 TURNOVER OF € 189 MILLION (+ 220%) | dataJanuary 25th, 2021
Read All

GENFIT: Sweeping approval of OCEANEs buyback and amendments of terms

By Dr. Matthew Watson

Lille, France; Cambridge, MA; January 25, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases (the “Company”), today announced the results of the shareholders’ vote at the Extraordinary Shareholders Meeting which took place on second convening this Monday, January 25, 2021 at 2:30pm (Paris time) (the “Extraordinary Shareholders Meeting”) and the voting results of the holders of the convertible bonds issued by the Company on October 16, 2017 (the “OCEANEs”) at the Bondholders Meeting which took place this Monday, January 25 2021 at 5:30pm (the “Bondholders Meeting”.) All resolutions proposed by the Board of Directors at both Meetings were approved with more than 98.5% of votes at the Extraordinary Shareholders Meeting and 100% of votes at the Bondholders Meeting.

Excerpt from:
GENFIT: Sweeping approval of OCEANEs buyback and amendments of terms

To Read More: GENFIT: Sweeping approval of OCEANEs buyback and amendments of terms
categoriaGlobal News Feed commentoComments Off on GENFIT: Sweeping approval of OCEANEs buyback and amendments of terms | dataJanuary 25th, 2021
Read All

Stem Cell Therapy Market to Witness Increase in Revenues by 2025 NeighborWebSJ – NeighborWebSJ

By daniellenierenberg

Stem Cell Therapy Market: Snapshot

Of late, there has been an increasing awareness regarding the therapeutic potential of stem cells for management of diseases which is boosting the growth of the stem cell therapy market. The development of advanced genome based cell analysis techniques, identification of new stem cell lines, increasing investments in research and development as well as infrastructure development for the processing and banking of stem cell are encouraging the growth of the global stem cell therapy market.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1787

One of the key factors boosting the growth of this market is the limitations of traditional organ transplantation such as the risk of infection, rejection, and immunosuppression risk. Another drawback of conventional organ transplantation is that doctors have to depend on organ donors completely. All these issues can be eliminated, by the application of stem cell therapy. Another factor which is helping the growth in this market is the growing pipeline and development of drugs for emerging applications. Increased research studies aiming to widen the scope of stem cell will also fuel the growth of the market. Scientists are constantly engaged in trying to find out novel methods for creating human stem cells in response to the growing demand for stem cell production to be used for disease management.

It is estimated that the dermatology application will contribute significantly the growth of the global stem cell therapy market. This is because stem cell therapy can help decrease the after effects of general treatments for burns such as infections, scars, and adhesion. The increasing number of patients suffering from diabetes and growing cases of trauma surgery will fuel the adoption of stem cell therapy in the dermatology segment.

Global Stem Cell Therapy Market: Overview

Also called regenerative medicine, stem cell therapy encourages the reparative response of damaged, diseased, or dysfunctional tissue via the use of stem cells and their derivatives. Replacing the practice of organ transplantations, stem cell therapies have eliminated the dependence on availability of donors. Bone marrow transplant is perhaps the most commonly employed stem cell therapy.

Osteoarthritis, cerebral palsy, heart failure, multiple sclerosis and even hearing loss could be treated using stem cell therapies. Doctors have successfully performed stem cell transplants that significantly aid patients fight cancers such as leukemia and other blood-related diseases.

Global Stem Cell Therapy Market: Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

To get Incredible Discounts on this Report, Click Here @ https://www.tmrresearch.com/sample/sample?flag=D&rep_id=1787

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

Request For TOC @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1787

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,3739 Balboa St # 1097,San Francisco, CA 94121United States

Tel: +1-415-520-1050

https://neighborwebsj.com/

Here is the original post:
Stem Cell Therapy Market to Witness Increase in Revenues by 2025 NeighborWebSJ - NeighborWebSJ

To Read More: Stem Cell Therapy Market to Witness Increase in Revenues by 2025 NeighborWebSJ – NeighborWebSJ
categoriaSkin Stem Cells commentoComments Off on Stem Cell Therapy Market to Witness Increase in Revenues by 2025 NeighborWebSJ – NeighborWebSJ | dataJanuary 25th, 2021
Read All

4 Doctors Reveal the Pros and Cons to Microneedling Treatments – NewBeauty Magazine

By daniellenierenberg

While the thought of dozens of tiny needles aimed directly at our faces sounds like a scare, microneedling may be worth it for the radiant skin it delivers. As with any trending procedure, it has its pros and consheres what four top doctors want you to know before scheduling an appointment.

It Opens Up the Skin BarrierMicroneedling creates little puncture sites in the skin, which allow for deeper product penetration, says Highland Park, IL plastic surgeon Steven P. Bloch, MD, who recommends combining the treatment with TCA peels that include hydrogen peroxide, exosomesthe healing, skin-calming growth factors derived from stem cellsor vitamins to stimulate collagen and elastin production. Applying medical-grade skin-care products after the procedure offers the best results because the skin will soak everything up much more effectively.

It Stimulates Collagen ProductionAs we age, our bodies produce less collagen (starting as early as our 20s), and therefore our skin begins to lose elasticity. However, Birmingham, AL dermatologist Corey Hartman, MD explains that microneedling promotes collagen production in our skin cells, helping it look as young as possible. Microneedling, which works on all skin types, administers small injuries to kick the bodys natural healing process into gear and rejuvenate the skin, he explains. Though there are only a few procedures in cosmetic dermatology that are truly preventive, microneedling delivers on the promise to stimulate fibroblasts, which synthesize the production of collagen.

ItCanBeEffectiveforTreatingMelasmaOne of the most common concerns women walk into our office with is melasma, says Grand Rapids, MI plastic surgeon Bradley Bengtson, MD. More often than not, melasma is not optimally treated with high-heat laser devices, so microneedling is a great tool to break up the pigment. The procedure banishes dark patches by allowing brightening creams and serums with ingredients like vitamin C to penetrate deep into the epidermal and dermal layers.

ItRequiresNoSkilltoUseAny Tom, Dick, Sally or Jane can buy a microneedling machine, set up a strip-mall shop and offer it to people, says Eagan, MN dermatologist Charles E. Crutchfield III, MD, who stresses that complications can arise if you dont visit a board-certified doctor for the treatment. Instead, he recommends an ablative laser, which also boosts collagen and tightens the skin with much more sophistication.

At NewBeauty, we get the most trusted information from the beauty authority delivered right to your inbox

Find a NewBeauty "Top Beauty Doctor" Near you

Go here to see the original:
4 Doctors Reveal the Pros and Cons to Microneedling Treatments - NewBeauty Magazine

To Read More: 4 Doctors Reveal the Pros and Cons to Microneedling Treatments – NewBeauty Magazine
categoriaSkin Stem Cells commentoComments Off on 4 Doctors Reveal the Pros and Cons to Microneedling Treatments – NewBeauty Magazine | dataJanuary 23rd, 2021
Read All

Here’s Why The Body Shop Is A Cult Brand to Know Plus The Best-Sellers To Buy – GLAMOUR UK

By daniellenierenberg

Body Shop stans, assemble! We have collated the best the brand has to offer to optimise your bathroom cabinet.

But before you start shopping, here are a few did you knows. This cruelty-free, British brand was the first international cosmetics brand to prohibit the use of ingredients tested on animals and one of the first to promote Fair Trade with third world countries. Earning its place as a household name over the past four decades plus a cult following, thanks to a diverse range of over 900 products, suitable for different skin tones and types and half of which are vegan.

For some insight, this Brighton-born beauty story dates back to 1976. It was founded by the iconic entrepreneur and human rights activist Dame Anita Roddick, pioneer to ethical consumerism, who wanted to create a high quality, revolutionary skincare range that would be a positive force in the beauty landscape. What differentiated Roddicks vision to other beauty giants was her desire to create the perfect harmony between quality, accessibility, environmental consciousness (starting out with refillable containers etc) and profit. That passion filtered through to employees - and the brand's ideology hasnt much changed along the years.

Helping disadvantaged communities is a brand priority and they have been sourcing their Community Fair Trade (CFT) shea butter from Tungteiya Womens Association in Northern Ghana since 1994. Where 640 women from 11 villages, handcraft shea butter using an 18-stage process of traditional techniques, successfully creating generational opportunities passed from mother to daughter. Their CFT handcrafted paper and gift packaging is also sustainably sourced from Kathmandu, Nepal.

A B Corp certified brand is amongst the 3,000 businesses worldwide to have the highest social and environmental standards for people and the planet. One focus is on using plant-based and recycled plastic (rather than oil-based plastics) and creating initiatives to aid consumers around the world to reuse, repurpose and recycle. In 2019, we reintroduced our pioneering refill scheme, a recycling programme and removed 21 tonnes of plastic from our gifts. says says Linda Campbell, Managing Director for the UK.

The ideals of The Body Shops founder had a direct impact on the direction of the brand. They havent shied away from supporting feminist movements, constantly raising the bar on ethical consciousness and fighting to empower girls and women across all demographics. The Body Shop have spent the last few years initiating and aligning with campaigns, most recently the Covid-19 response derived #IsolatedNotAlone campaign. With the objective of raising awareness on domestic abuse and providing potentially life-saving resources for survivors and bystanders at increased risk during lockdown measures." says Campbell.

If all this doesnt make you feel more passionate about the brand, we dont know what will. And that's before we even get the quality products at consumer friendly prices. But dont let the Body Shop name fool you though, as not only extensive bath and body sup, but skincare, haircare and vegan makeup.

If youre a lover of newness, you might want to investigate the latest drop, which includes Hemp Dry Body Oil, 14, and the Drops of Youth Bouncy Jelly Mist, 16. A gel-to-mist formula protect the skin from indoor and outdoor pollution as well as the effects of blue light from all the Zooming.

But the beauty giant is just as loved for its cult products, from the nourishing glow masks to their world famous body butters (which sell at a rate of one every three seconds). If you want to know what the hype is really about, here is a selection of the 10 bestselling products and why they deserve a spot in your bathroom cabinet.

Read more:
Here's Why The Body Shop Is A Cult Brand to Know Plus The Best-Sellers To Buy - GLAMOUR UK

To Read More: Here’s Why The Body Shop Is A Cult Brand to Know Plus The Best-Sellers To Buy – GLAMOUR UK
categoriaSkin Stem Cells commentoComments Off on Here’s Why The Body Shop Is A Cult Brand to Know Plus The Best-Sellers To Buy – GLAMOUR UK | dataJanuary 23rd, 2021
Read All

Ohio State establishing national standards for ALS genetic testing, research and patient care | Ohio State Medical Center – Wexner Medical Center -…

By daniellenierenberg

Led by genetic counselor Jennifer Roggenbuck, MS, LGC, a one-year grant awarded by the ALS Association is funding Ohio States formal development of national clinical guidelines for ALS genetic testing that will be used by healthcare centers nationwide. We have cared for thousands of patients since opening our ALS/MND Clinic in the mid-1990s and have extensive experience with genetic testing, says Roggenbuck. We believe its extremely important to establish national testing standards, to ensure that all persons with ALS can benefit from genetic advances, and to fuel further research.

Genetic testing and counseling directly benefits our patients, explains clinic director Stephen J. Kolb, MD, PhD. Genetic characterization of our patients also opens the door to research opportunities. In addition to formal genetic counseling, our clinic has an ALS Clinical Research Coordinator who meets with every patient to explain our basic science and clinical trial opportunities and answer any related questions. Our patient partnerships are a key factor in the size and scope of our research program. Because Ohio State is now among the largest ALS research sites in the country, were regularly asked to participate in or lead high profile National Institutes of Health (NIH) and foundation studies.

A major focus of our program is to connect the individuals that we serve in clinic to the critical research efforts that are happening in laboratories here at Ohio State as well as those throughout the world. One example of this is the development of individualized models of disease, says Dr. Kolb. We and our collaborators are able to biopsy a persons skin cells and turn them into a type of stem cell that allow us to reproduce each patients exact ALS condition in the laboratory. We can then study the models to look for causes and develop therapies on a case-by-case basis.

The ALS/MND Multidisciplinary Clinic and Research Program is part of Ohio States Neurological Institute, with one of the largest neuromuscular centers in the country, so there is an established team of multidisciplinary experts to help each patient, even those with unusual or difficult symptoms. The ALS/MND program is led by Kolb, a physician-scientist, and in addition to the full-time research coordinator, he is joined by a clinical neurologist, genetic counselor, clinical nurse practitioner, social worker and nutritionist, as well as physical, occupational, respiratory and speech therapists. The Ohio State Department of Neurology is a member of NeuroNEXT: Network for Excellence in Neuroscience Clinical Trials and a contributing member to the Northeast ALS Consortium (NEALS).

Read feature stories

Go here to read the rest:
Ohio State establishing national standards for ALS genetic testing, research and patient care | Ohio State Medical Center - Wexner Medical Center -...

To Read More: Ohio State establishing national standards for ALS genetic testing, research and patient care | Ohio State Medical Center – Wexner Medical Center -…
categoriaSkin Stem Cells commentoComments Off on Ohio State establishing national standards for ALS genetic testing, research and patient care | Ohio State Medical Center – Wexner Medical Center -… | dataJanuary 23rd, 2021
Read All

Global Regenerative Medicine Market Insights, Overview, Analysis and Forecast 2022 NeighborWebSJ – NeighborWebSJ

By daniellenierenberg

Regenerative Medicine Market Major Players:

Players active in the global regenerative medicine market include Osiris Therapeutics, Cook Biotech, Organogenesis, Baxter International, Inc., Stryker and RTI surgical, LifeSciences, CryoLife, Advanced Cell Technology, Sanofi, BioMimetic Therapeutics, Medtronic, StemCellsInc, and LifeCell Kinetic Concepts, among others.

ALSO READ :https://sapanas.tumblr.com/post/631130245458739200/regenerative-medicine-market-competitive-analysis

Regenerative Medicine Market Outlook

Global regenerative medicine market is growing continually, witnessing a massive uptake. Market growth primarily attributes to the increasing advancement in healthcare technology and the growing prevalence of chronic diseases. Besides, improvements in the field of regenerative medicine and stem cell technology drive the growth of the market excellently.

Moreover, the rising uptake of therapeutics such as stem cell biology, cellular therapy, tissue engineering in applications, including cord blood, oncology, urology, orthopedics, neurology, dermatology, and others accelerate the market growth. According to Market Research Future (MRFR), the global regenerative medicine market is poised to grow at 25.4% CAGR throughout the forecast period (2016 2022).

ALSO READ :https://yarabook.com/read-blog/138540

Additionally, the rising uptake of stem cell & tissue engineering processes in the treatment of health issues ranging from orthopedics, musculoskeletal & spine, dental, and skin/integumentary to cancer, neurology, and cardiology substantiate the market growth. Furthermore, the increasing rate of road accidents, injuries, and trauma cases drive the market exponentially, driving the demand for transplants & surgical reconstruction procedures.

On the other hand, factors such as the lack of awareness, skilled professionals, and stringent regulatory policies are projected to act as significant impeders for market growth. Nevertheless, funding support for the development of regenerative medicines would support the growth of the market throughout the predicted period. Also, widening application areas of regenerative medicines in the field of stem cell reconstructive and skin grafting would increase the market growth.

Global Regenerative Medicine Market Segments

The analysis is segmented into four dynamics;

By Material: Synthetic Materials, Genetically Engineered Materials, Pharmaceuticals, and others.

By Therapy: Stem Cell Biology, Cellular Therapy, Tissue Engineering, and others.

By Application: Cord Blood, Oncology, Urology, Orthopedics, Neurology, Dermatology, and others.

ALSO READ :http://www.marketwatch.com/press-release/fram-market-2021-industrytrends-opportunities-market-volume-competitive-landscape-possible-challenges-and-forecast-to-2025-2021-01-06

By Regions: Americas, Europe, Asia Pacific, Middle East & Africa, and Rest-of-the-World.

Regenerative Medicine Market Regional Analysis

North America is projected to continue dominating the globalregenerative medicine marketthroughout the forecast period. In 2015, North America accounted for more than 44% of the overall market share. This huge market growth attributes to the presence of a large number of major players and pharma & biotechnology companies. Moreover, huge investments made by public & private organizations drive the regenerative medicine industry in the region.

Besides, the rising prevalence of chronic diseases and orthopedic issues and increasing clinical trials to evaluate the therapeutic potential of products foster regional market growth. Also, the well-spread awareness towards the therapeutic potency of regenerative medicines impacts the market growth positively. The North American regenerative medicine market is expected to grow at a robust CAGR of 22.3% over the review period.

Europe stands second in the global regenerative medicine market. Factors such as the increasing per capita healthcare expenses and penetration of healthcare sectors in the region boost the market growth. Additionally, the rising government support and R&D funding in the life science developments substantiate the regional market growth. Markets in the UK, Germany, and France, contribute to the regional market majorly. The European regenerative medicine market is estimated to grow at 22.5% CAGR during the assessment period.

ALSO READ :http://www.marketwatch.com/press-release/m2m-communication-market-demand-to-rise-amid-industrial-automation-industry-analysis-with-business-trends-covid19-outbreak-competitor-strategyforecast-to-2023-2021-01-05

The Asia Pacific regenerative medicine market has emerged as a rapidly growing market. Factors such as the large advances in biotechnology and increasing government support for R&D are fostering the growth of the regional market. Regenerative medicine markets in highly populated countries such as China, India, and Japan support the regional market growth excellently, heading with huge technological advances. The APAC Regenerative Medicine market is predicted to demonstrate huge growth potential.

Global Regenerative Medicine Market Competitive Analysis

The well-established regenerative medicine market appears to be highly competitive with the presence of several notable players. To gain a larger competitive advantage, market players incorporate strategic initiatives such as mergers & acquisitions, expansions, and product/technology launch. Also, they make substantial investments to drive R&D to develop their capabilities and to expand their global footprints. Simultaneously, R&D funding programs initiated by the governments to enhance regenerative medicine capabilities are offering high growth potential. This is further going to attract several new entrants to the market and intensify the market competition further.

Regenerative Medicine Industry/Innovations/Related News:

March 15, 2020 - Research team at the University of Sheffield published their study on stem cell mutations that could improve regenerative medicine in the magazine Stem Cell Reports. Their study gives new insights into the cause of mutations in pluripotent stem cells and potential ways of stopping these mutations from occurring. It also suggests ways to reduce the likelihood of variations occurring in these cells when cultured. There is considerable interest in using Pluripotent stem cells to produce cells that can replace diseased or damaged tissues in applications referred to as regenerative medicine.

ALSO READ :http://www.marketwatch.com/press-release/waste-to-energy-market-share-size-key-players-regional-study-and-forecast-2024-2020-12-30

https://neighborwebsj.com/

Read this article:
Global Regenerative Medicine Market Insights, Overview, Analysis and Forecast 2022 NeighborWebSJ - NeighborWebSJ

To Read More: Global Regenerative Medicine Market Insights, Overview, Analysis and Forecast 2022 NeighborWebSJ – NeighborWebSJ
categoriaSkin Stem Cells commentoComments Off on Global Regenerative Medicine Market Insights, Overview, Analysis and Forecast 2022 NeighborWebSJ – NeighborWebSJ | dataJanuary 23rd, 2021
Read All

CorMedix Inc. to Begin Trading on the Nasdaq Stock Exchange

By Dr. Matthew Watson

BERKELEY HEIGHTS, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has been approved for listing on the Nasdaq Global Market. The company’s shares will continue to trade under its current symbol “CRMD”. Trading on the Nasdaq Global Market is expected to commence on Tuesday, February 2, 2021. The Company’s shares of common stock will continue to trade on the NYSE American until the close of the market on Monday, February 1, 2021.

Read more:
CorMedix Inc. to Begin Trading on the Nasdaq Stock Exchange

To Read More: CorMedix Inc. to Begin Trading on the Nasdaq Stock Exchange
categoriaGlobal News Feed commentoComments Off on CorMedix Inc. to Begin Trading on the Nasdaq Stock Exchange | dataJanuary 23rd, 2021
Read All

Codiak’s Versatile engEx™ Platform for Engineered Exosomes Published in the Journal Molecular Therapy

By Dr. Matthew Watson

– New publication details the characterization of novel scaffold proteins that can enable engineered exosomes with defined therapeutic properties –

The rest is here:
Codiak’s Versatile engEx™ Platform for Engineered Exosomes Published in the Journal Molecular Therapy

To Read More: Codiak’s Versatile engEx™ Platform for Engineered Exosomes Published in the Journal Molecular Therapy
categoriaGlobal News Feed commentoComments Off on Codiak’s Versatile engEx™ Platform for Engineered Exosomes Published in the Journal Molecular Therapy | dataJanuary 23rd, 2021
Read All

Trishula Therapeutics Appoints Anil Singhal as Chief Executive Officer

By Dr. Matthew Watson

See the original post:
Trishula Therapeutics Appoints Anil Singhal as Chief Executive Officer

To Read More: Trishula Therapeutics Appoints Anil Singhal as Chief Executive Officer
categoriaGlobal News Feed commentoComments Off on Trishula Therapeutics Appoints Anil Singhal as Chief Executive Officer | dataJanuary 23rd, 2021
Read All

Auxly Announces Upsized Bought-Deal Public Offering to $17.5 Million

By Dr. Matthew Watson

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

Originally posted here:
Auxly Announces Upsized Bought-Deal Public Offering to $17.5 Million

To Read More: Auxly Announces Upsized Bought-Deal Public Offering to $17.5 Million
categoriaGlobal News Feed commentoComments Off on Auxly Announces Upsized Bought-Deal Public Offering to $17.5 Million | dataJanuary 23rd, 2021
Read All

MDxHealth Launches Capital Increase and Provides Preliminary 2020 Financial Results

By Dr. Matthew Watson

THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW

See the original post here:
MDxHealth Launches Capital Increase and Provides Preliminary 2020 Financial Results

To Read More: MDxHealth Launches Capital Increase and Provides Preliminary 2020 Financial Results
categoriaGlobal News Feed commentoComments Off on MDxHealth Launches Capital Increase and Provides Preliminary 2020 Financial Results | dataJanuary 23rd, 2021
Read All

Hollister Biosciences Inc. Announces an Increase in Private Placement to $6.5 Million

By Dr. Matthew Watson

** THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.**

Read the original:
Hollister Biosciences Inc. Announces an Increase in Private Placement to $6.5 Million

To Read More: Hollister Biosciences Inc. Announces an Increase in Private Placement to $6.5 Million
categoriaGlobal News Feed commentoComments Off on Hollister Biosciences Inc. Announces an Increase in Private Placement to $6.5 Million | dataJanuary 23rd, 2021
Read All

DEINOVE strengthens its Business development team to deploy its partnering strategy

By Dr. Matthew Watson

DEINOVE strengthens its Business development team to deploy its partnering strategy

Read more:
DEINOVE strengthens its Business development team to deploy its partnering strategy

To Read More: DEINOVE strengthens its Business development team to deploy its partnering strategy
categoriaGlobal News Feed commentoComments Off on DEINOVE strengthens its Business development team to deploy its partnering strategy | dataJanuary 23rd, 2021
Read All

Page 176«..1020..175176177178..190200..»


Copyright :: 2024